Skip to search formSkip to main contentSkip to account menu

oblimersen sodium

Known as: Augmerosen, DNA, D(P-thio)(T-C-T-C-C-C-A-G-C-G-T-G-C-G-C-C-A-T) hepatadecasodium salt 
The sodium salt of a phosphorothioate antisense oligonucleotide targeted to the initiation codon region of mRNA for the anti-apoptotic gene Bcl-2… 
National Institutes of Health

Related topics

Related topics

3 relations
G-3139 oligonucleotide

Narrower (1)

Genasense

Broader (1)

oblimersen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)
Advanced hepatocellular (HCC) is refractory to most standard forms of chemotherapy, however responses to doxorubicin are seen [1… 
2006
2006
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
PURPOSE To assess the feasibility and antitumor activity of oblimersen sodium, an antisense oligonucleotide directed to the Bcl-2… 
2005
2005
Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM…
7506 Background: Chemotherapy resistance of MM has been linked to anti-apoptotic proteins, including Bcl-2 that is over-expressed… 
2004
2004
Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term…
7505 Background: Chemotherapy resistance of MM has been linked to Bcl-2, an anti-apoptotic protein over-expressed in > 80% of pts… 
Review
2004
Review
2004
Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense; Genasense; G3139) for Patients with Relapsed or Refractory Chronic…
Bcl-2 is an anti-apoptotic protein that has been closely linked to chemotherapy resistance and inferior survival in patients (pts… 
2004
2004
Randomized Multicenter Phase 3 Trial of High-Dose Dexamethasone (dex) with or without Oblimersen Sodium (G3139; Bcl-2 antisense; Genasense) for Patients with Advanced Multiple Myeloma (MM).
Over-expression of Bcl-2 has been linked to acquired dex resistance in MM cells. Conversely, reduction of Bcl-2 using oblimersen… 
Review
2004
Review
2004
Management of metastatic cutaneous melanoma.
The results of treatment for metastatic melanoma remain disappointing. Single-agent chemotherapy produces response rates ranging… 
Review
2004
Review
2004
Potential therapeutic applications of oblimersen in CLL.
Bcl-2 protein is upregulated in a wide variety of lymphoid malignancies, including chronic lymphocytic leukemia (CLL). The… 
2004
2004
A Pilot Study of Genasense® (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.
Bcl-2 is an anti-apoptotic protein closely linked to chemotherapy resistance and inferior survival in patients (pts) with CLL… 
Review
2003
Review
2003
Proapoptotische Therapie mit Oblimersen (bcl-2-Antisense-Oligonukleotid) – Übersicht über präklinische und klinische Daten
Proapoptotic Therapy with Oblimersen (bcl-2 Antisense Oligonucleotide) – Review of Preclinical and Clinical Results The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)